Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives $47.50 Consensus Target Price from Analysts

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) have been given a consensus rating of “Buy” by the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $47.50.

PVLA has been the topic of several recent analyst reports. Canaccord Genuity Group decreased their price target on Palvella Therapeutics from $53.00 to $52.00 and set a “buy” rating on the stock in a research note on Friday, May 16th. Chardan Capital initiated coverage on Palvella Therapeutics in a research note on Wednesday, April 9th. They issued a “buy” rating and a $50.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $38.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, April 30th. Finally, Truist Financial initiated coverage on Palvella Therapeutics in a report on Monday, July 21st. They issued a “buy” rating and a $56.00 price objective on the stock.

Institutional Investors Weigh In On Palvella Therapeutics

Several large investors have recently bought and sold shares of the stock. Suvretta Capital Management LLC purchased a new stake in Palvella Therapeutics during the 4th quarter worth about $8,574,000. BVF Inc. IL purchased a new position in shares of Palvella Therapeutics in the 4th quarter valued at about $8,359,000. Frazier Life Sciences Management L.P. increased its holdings in shares of Palvella Therapeutics by 5.5% in the 1st quarter. Frazier Life Sciences Management L.P. now owns 690,012 shares of the company’s stock valued at $19,313,000 after acquiring an additional 36,120 shares during the last quarter. Samsara BioCapital LLC purchased a new position in shares of Palvella Therapeutics in the 4th quarter valued at about $8,154,000. Finally, Adams Street Partners LLC purchased a new position in shares of Palvella Therapeutics in the 4th quarter valued at about $4,916,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Stock Performance

NASDAQ PVLA opened at $37.44 on Monday. The stock’s fifty day moving average is $26.46 and its two-hundred day moving average is $23.03. The firm has a market capitalization of $414.09 million, a P/E ratio of -3.09 and a beta of -0.11. Palvella Therapeutics has a fifty-two week low of $11.17 and a fifty-two week high of $40.50.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.40) by $2.66. As a group, sell-side analysts forecast that Palvella Therapeutics will post -3.69 EPS for the current year.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.